Dr. Zachary D Crees, M.D.
Claim this profileWashington University School of Medicine
Area of expertise
Multiple Myeloma
Zachary D Crees, M.D. has run 4 trials for Multiple Myeloma.
Hemangioblastoma
Zachary D Crees, M.D. has run 1 trial for Hemangioblastoma. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Clinical Trials Zachary D Crees, M.D. is currently running
CAR-T Therapy
for Multiple Myeloma
Despite recent therapeutic advances, multiple myeloma (MM) remains an incurable disease. Although survival has improved, there are nevertheless diminishing durations of response to each subsequent line of therapy. This highlights the need for further therapeutic innovation. BCMA-targeting CAR-T cells show impressive response rates; however, their median duration of response is disappointing. The investigators propose that CS1(SLAMF7)-targeting CAR-T cells will fill a gap in the MM armamentarium. CS1 is an attractive target in MM because it is expressed in most patients. Elotuzumab (Empliciti®), an approved anti-CS1 antibody, has proven the clinical efficacy of this target. CAR-T cells are an ideal modality to target CS1, given that two approved treatments, ide-cel (idecabtagene vicleucel, AbecmaTM) and cilta-cel (ciltacabtagene autoleucel, Carvykti™), have proven the potential for cellular immunotherapy in MM. The investigators are testing the safety and preliminary anti-myeloma efficacy of WS-CART-CS1, a CAR-T cell therapy targeting CS1.
Recruiting
1 award
Phase 1
Ruxolitinib
for Graft-Versus-Host Disease Prevention
Allogeneic hematopoietic cell transplantation (HCT) is one of the only curative intent therapies available for hematologic malignancies. HLA-matched sibling donors have historically offered the best clinical results but are unavailable for the majority of patients, while most patients do have readily available haploidentical donors. One of the risks of a haploidentical HCT is graft vs. host disease (GVHD), but it is difficult to reduce the incidence of GVHD without compromising the graft vs. leukemia (GVL) effect. The hypothesis of this study is that JAK inhibition with and without CTLA-4 Ig with haploidentical HCT may mitigate GVHD and cytokine release syndrome while retaining the GVL effect and improving engraftment.
Recruiting
1 award
Phase 1
More about Zachary D Crees, M.D.
Clinical Trial Related
1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Zachary D Crees, M.D. has experience with
- Motixafortide
- Leukapheresis
- Natalizumab
- Flotetuzumab
- MGD006
- Donor Lymphocyte Infusion
Breakdown of trials Zachary D Crees, M.D. has run
Multiple Myeloma
Hemangioblastoma
Sickle Cell Disease
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Zachary D Crees, M.D. specialize in?
Zachary D Crees, M.D. focuses on Multiple Myeloma and Hemangioblastoma. In particular, much of their work with Multiple Myeloma has involved treating patients, or patients who are undergoing treatment.
Is Zachary D Crees, M.D. currently recruiting for clinical trials?
Yes, Zachary D Crees, M.D. is currently recruiting for 3 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Zachary D Crees, M.D. has studied deeply?
Yes, Zachary D Crees, M.D. has studied treatments such as Motixafortide, Leukapheresis, Natalizumab.
What is the best way to schedule an appointment with Zachary D Crees, M.D.?
Apply for one of the trials that Zachary D Crees, M.D. is conducting.
What is the office address of Zachary D Crees, M.D.?
The office of Zachary D Crees, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.